Journal Wrap | ORFAN: Refining Risk Reclassification; RESPECT-EPA: Reducing Secondary Outcomes
The hottest research from various peer-reviewed journals – handpicked weekly by the ACC.org Editorial Board led by Kim A. Eagle, MD, MACC.
ORFAN: FAI Score Obtained During CCTA, AI-Risk Algorithm Refine Risk Reclassification
Coronary computed tomography (CCTA), used for first-line investigation of chest pain, has revealed there is a large group of individuals without obstructive coronary artery disease (CAD) for whom there is an unclear prognosis and management. Defining inflammatory risk using the perivascular fat attenuation index (FAI) Score has been shown to enhance clinical risk stratification and CCTA interpretation, according to results from the ORFAN study published in The Lancet.
RESPECT-EPA: IPE Reduces Number of MACE, Significantly Reduces Secondary Outcomes
Icosapent ethyl (IPE) treatment may be associated with a numerically lower risk of cardiovascular events, but this reduction did not reach statistical significance in patients with chronic coronary artery disease (CAD) and a low ratio of eicosapentaenoic acid to arachidonic acid (EPA/AA) on statin treatment, according to the results of the RESPECT-EPA study published in Circulation.
Clinical Topics: Arrhythmias and Clinical EP, Dyslipidemia, Atherosclerotic Disease (CAD/PAD), SCD/Ventricular Arrhythmias, Atrial Fibrillation/Supraventricular Arrhythmias, Lipid Metabolism, Nonstatins
Keywords: Cardiology Magazine, ACC Publications, Coronary Artery Disease, Risk Assessment, Chest Pain, Artificial Intelligence, Plaque, Atherosclerotic, Eicosapentaenoic Acid, Death, Sudden, Cardiac, Atrial Fibrillation, Ischemic Stroke
